Genetic and epigenetic alteration of the RAS–RAF–MEK–MAPK–ERK pathway, and mutations in NRAS, KRAS, and BRAF, have been shown to strongly influence the development of thyroid cancers [7,8,9]. This evidence concerns the gene KRAS and thyroid gland carcinoma.